William Blair reissued their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report released on Friday, AnalystRatings.com reports.
Several other equities research analysts also recently issued reports on ALXN. Raymond James set a $168.00 target price on shares of Alexion Pharmaceuticals and gave the company a buy rating in a research note on Friday, August 30th. Piper Jaffray Companies set a $180.00 price objective on Alexion Pharmaceuticals and gave the company a buy rating in a research note on Friday, September 6th. Robert W. Baird set a $165.00 price objective on Alexion Pharmaceuticals and gave the company a buy rating in a research report on Friday, August 30th. Evercore ISI reiterated a buy rating and set a $145.00 target price on shares of Alexion Pharmaceuticals in a research note on Sunday, November 17th. Finally, TheStreet lowered Alexion Pharmaceuticals from a b- rating to a c+ rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $156.37.
Shares of ALXN opened at $113.89 on Friday. The company has a market cap of $25.20 billion, a price-to-earnings ratio of 12.45, a PEG ratio of 0.87 and a beta of 1.67. Alexion Pharmaceuticals has a 1-year low of $92.56 and a 1-year high of $141.86. The company’s fifty day simple moving average is $108.47 and its 200 day simple moving average is $112.81. The company has a current ratio of 3.98, a quick ratio of 3.45 and a debt-to-equity ratio of 0.25.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.32. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter last year, the company posted $2.02 earnings per share. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. As a group, research analysts forecast that Alexion Pharmaceuticals will post 9.43 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Alexion Pharmaceuticals by 1.3% in the second quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after buying an additional 211,960 shares in the last quarter. BlackRock Inc. grew its position in Alexion Pharmaceuticals by 1.2% during the second quarter. BlackRock Inc. now owns 16,225,615 shares of the biopharmaceutical company’s stock worth $2,125,230,000 after buying an additional 199,298 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Alexion Pharmaceuticals by 57,650.8% during the 2nd quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock worth $476,393,000 after acquiring an additional 3,630,846 shares during the period. Northern Trust Corp increased its stake in Alexion Pharmaceuticals by 0.5% during the 2nd quarter. Northern Trust Corp now owns 2,976,327 shares of the biopharmaceutical company’s stock worth $389,840,000 after acquiring an additional 15,296 shares during the period. Finally, Bank of America Corp DE raised its holdings in Alexion Pharmaceuticals by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 2,078,585 shares of the biopharmaceutical company’s stock valued at $272,253,000 after acquiring an additional 13,426 shares in the last quarter. Hedge funds and other institutional investors own 91.62% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Story: Trading Strategy
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.